Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Flat-coated retrievers set to benefit from new cancer research
Flat-coated retrievers are particularly susceptible to histiocytic sarcoma.

Simple blood test could allow for the early detection of the disease

One of the UK’s native gun dogs, the flat-coated retriever, is set to benefit from new research into a rare but aggressive form of cancer.


Research shows more than 50 per cent of flat-coated retrievers die of cancer and the breed is particularly susceptible to histiocytic sarcoma (HS) - a type of cancer found in multiple locations across the body. The outlook for the disease is extremely poor and, in most cases, terminal. 

Now scientists at the Animal Health Trust (AHT) and the University of Cambridge are set to carry out new research into the creation of a blood test for the early detection of HS in flat-coated retrievers. An early diagnosis would improve the chances of successful treatment and extend survival time.


Dr Anna Hollis, a cancer researcher at the AHT, said: “I have flat-coated retrievers and have lost one of them to histiocytic sarcoma - it is absolutely devastating. This research could make a significant difference, and that is a huge personal motivation for me."

In the study, researchers plan to confirm if there is a specific microRNA ‘signature’ that is unique to HS amongst tumours and tissue samples from flat-coated retrievers. MicroRNAs are often found in tumours and vary between different types of cancer.

If such a signature is identified, the project will investigate if measuring the levels of these microRNAs within a flat-coated retriever tissue sample can be used to identify a histiocytic sarcoma.

Should the team identify a microRNA ‘signature’ in histiocytic tumours, they will then seek additional funding to see if the same signature can be identified in the blood of affected dogs. If they find a microRNA signature, this could potentially be identified by a single blood test.


This would mean that a blood sample from a flat-coated retriever that was lame could be tested for the presence of HS-associated microRNAs - allowing for the disease to be detected at an earlier stage.

Dr Hollis continued: “Often lame dogs are rested and given pain relief before imaging is sought. Delayed diagnosis is a potential problem with histiocytic sarcoma given its aggressive nature and ability to spread rapidly to other locations within the body. 


"If we could identify affected dogs at an earlier stage, this may allow more successful treatment of the disease.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.